Sysco Aktie News

Sysco's profit margins are rising even as it faces higher food costs. Management sees accelerating growth in the second half of fiscal 2026.

Sysco Corporation (SYY) Q2 2026 Earnings Call Transcript

Sysco Corporation remains a Hold as shares trade near fair value, reflecting resilient local demand but ongoing macro headwinds. Margin pressure from higher compensation and weak restaurant traffic constrain near-term growth despite SYY's market share gains and international momentum. EPS guidance has improved to the upper half of $4.50–$4.60, supported by overseas growth and a weaker U.S. dollar.

Food distributor Sysco lifted its annual profit forecast and beat estimates for both second-quarter profit and sales on Tuesday, as strong demand for its steaks, fillets and frozen-food products helped the company's U.S. business continue its recovery.

Sysco's fiscal second-quarter net income fell, but the food-supplies giant said it was set to hit the high end of its previous full-year adjusted-earnings projection.

HOUSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sysco Corporation (NYSE:SYY) (“Sysco” or the “company”) today announced financial results for its 13-week second fiscal quarter ended December 27, 2025. Key financial results for the second quarter of fiscal year 2026 include the following (comparisons are to the same period in fiscal year 2025): Sales increased 3.0%; U.S. Foodservice volume increased ...

Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23rd, outpacing SPY's 1.07% gain. Nineteen Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%.

Ashtead has also been moving its primary listing to the New York Stock Exchange, which we believe will lift its valuation. Wells Fargo delivered strong earnings results driven by higher revenue, improved credit quality and higher investment banking fees. Merck reported earnings and revenues that beat expectations, driven by strong sales of its cancer treatment Keytruda and its pulmonary arteria...